Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion

Journal of Infectious Diseases

Volumn 211, Issue 6, 2015, Pages 947-955

  Bogers, Willy M ^a   Oostermeijer, Herman ^a   Mooij, Petra ^a   Koopman, Gerrit ^a   Verschoor, Ernst J ^a   Davis, David ^a   Ulmer, Jeffrey B ^b   Brito, Luis A ^b   Cu, Yen ^b   Banerjee, Kaustuv ^b   Otten, Gillis R ^b   Burke, Brian ^b   Dey, Antu ^b   Heeney, Jonathan L ^e   Shen, Xiaoying ^c   Tomaras, Georgia D ^c,d   Labranche, Celia ^d   Montefiori, David C ^d   Liao, Hua Xin ^c,d   Haynes, Barton ^c,d   Geall, Andrew J ^b   Barnett, Susan W ^b   more..

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b Novartis Vacccines   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

antibodies; HIV; self amplifying mRNA; T cells; vaccine

Indexed keywords

ADJUVANT; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MESSENGER RNA; MIFAMURTIDE; NEUTRALIZING ANTIBODY; RNA VACCINE; SELF AMPLIFYING MESSENGER RNA; SELF AMPLIFYING MESSENGER RNA VACCINE; UNCLASSIFIED DRUG; VIRAL REPLICON PARTICLE VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS RNA; VIRUS VACCINE; CATION; EMULSION; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CATIONIC NANOEMULSION; CELLULAR IMMUNITY; CLADISTICS; CONTROLLED STUDY; DRUG SAFETY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; NANOEMULSION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIMATE; PRIORITY JOURNAL; REPEATED DRUG DOSE; REPLICON; RHESUS MONKEY; RNA VECTOR; RNA VIRUS; VACCINATION; ADAPTIVE IMMUNITY; ANIMAL; BLOOD; CELL CULTURE; EMULSION; GENETICS; HIV INFECTIONS; IMMUNOLOGY; OUTBRED STRAIN;

ADAPTIVE IMMUNITY; AIDS VACCINES; ANIMALS; ANIMALS, OUTBRED STRAINS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CATIONS; CELLS, CULTURED; EMULSIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; IMMUNITY, CELLULAR; MACACA MULATTA; MALE; RNA, VIRAL;

EID: 84924405861     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu522     Document Type: Article

References (50)

1. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8:108-20
2. Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282:476-80
3. Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 2003; 21:4604-8
4. Pascolo S. Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol 2008; 183:221-35
5. Weiss R, Scheiblhofer S, Roesler E, Weinberger E, Thalhamer J. mRNA vaccination as a safe approach for specific protection from type I allergy. Expert Rev Vaccines 2012; 11:55-67
6. Kallen KJ, Heidenreich R, Schnee M, et al. A novel, disruptive vaccination technology: Self-adjuvanted RNActive vaccines. Hum Vaccin Immunother 2013; 9:2263-76
7. Tavernier G, Andries O, Demeester J, et al. mRNA as gene therapeutic: how to control protein expression. J Control Release 2011; 150:238-47
8. Geall AJ, Mandl CW, Ulmer JB. RNA: the new revolution in nucleic acid vaccines. Semin Immunol 2013; 25:152-9
9. Kutzler MA, Weiner DB. DNAvaccines: ready for prime time?. Nat Rev Genet 2008; 9:776-88
10. McConkey SJ, Reece WH, Moorthy VS, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9:729-35
11. Harari A, Bart PA, Stohr W, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008; 205:63-77
12. Goonetilleke N, Moore S, Dally L, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 2006; 80:4717-28
13. Wang S, Kennedy JS, West K, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26:3947-57
14. Nwanegbo E, Vardas E, Gao W, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004; 11:351-7
15. Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type- 36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010; 28:950-7
16. Santra S, Seaman MS, Xu L, et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 2005; 79:6516-22
17. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8
18. Schalk JA, Mooi FR, Berbers GA, et al. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin 2006; 2:45-53
19. Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA 2012; 109:14604-9
20. Ulmer JB, Mason PW, Geall A, Mandl CW. RNA-based vaccines. Vaccine 2012; 30:4414-8
21. Hekele A, Bertholet S, Archer J, et al. Rapidly produced SAM vaccine against H7N9 influenza is immunogenic in mice. Emerging Microbes Infections 2013; 2:e52, 1-7
22. Perri S, Greer CE, Thudium K, et al. An alphavirus replicon particle chimera derived fromVenezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 2003; 77:10394-403
23. Brito L, Chan M, ShawC, et al.Acationic nanoemulsion for the delivery of next generation RNAvaccines. Mol Ther 2014; doi:10.1038/mt.2014.133
24. Gupta RK, Siber GR. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 1995; 13:1263-76
25. Ansaldi F, Canepa P, Parodi V, et al. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine 2009; 27:3345-8
26. Smerdou C, Liljestrom P. Non-viral amplification systems for gene transfer: vectors based on alphaviruses. Curr Opin Mol Ther 1999; 1:244-51
27. Spearman P, Lally MA, Elizaga M, et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis 2011; 203:1165-73
28. Ott G, Singh M, Kazzaz J, et al. A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNAvaccines. J Control Release 2002; 79:1-5
29. Srivastava IK, Stamatatos L, Legg H, et al. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol 2002; 76:2835-47
30. Srivastava IK, Kan E, Sun Y, et al. Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates. Virology 2008; 372:273-90
31. Calabro S, Tortoli M, Baudner BC, et al. Vaccine adjuvants alum andMF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011; 29:1812-23
32. Mooij P, Bogers WM, Oostermeijer H, et al. Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy. J Virol 2000; 74:4017-27
33. Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008; 82:12449-63
34. Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013; 369:2083-92
35. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-86
36. Zolla-Pazner S, deCamp A, Gilbert PB, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 2014; 9:e87572
37. Liao HX, Bonsignori M, Alam SM, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013; 38:176-86
38. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigenspecific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004; 286:111-22
39. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000; 74:8358-67
40. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-905
41. Davis D, Koornstra W, Mortier D, et al. Protection in macaques immunized with HIV-1 candidate vaccines can be predicted using the kinetics of their neutralizing antibodies. PLoS One 2011; 6:e28974
42. Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108-25
43. Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 2009; 485:395-405
44. Seaman MS, Janes H, Hawkins N, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 2010; 84:1439-52
45. Koopman G, Mortier D, Hofman S, et al. Acute-phase CD4+ T-cell proliferation and CD152 upregulation predict set-point virus replication in vaccinated simian-human immunodeficiency virus strain 89.6p-infected macaques. J Gen Virol 2009; 90:915-26
46. Ulmer JB, Sztein MB. Promising cutting-edge technologies and tools to accelerate the discovery and development of new vaccines. Curr Opin Immunol 2011; 23:374-6
47. Deering RP, Kommareddy S, Ulmer JB, Brito LA, Geall AJ. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin Drug Deliv 2014; 11: 885-99
48. Bernstein DI, Reap EA, Katen K, et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009; 28:484-93
49. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 2011; 23:421-9
50. Pascolo S. Messenger RNA-based vaccines. Expert Opin Biol Ther 2004; 4:1285-94